金斯瑞(01548.HK)與鎮江委員會訂立投資協議 斥1.8億人幣投資建廠
金斯瑞生物科技(01548.HK)公布,與鎮江委員會訂立投資協議,鎮江委員會將以零租金向金斯康香港提供合共20,000平方米的三間工廠,租期五年,連同於五年租期結束後按相同條件向金斯康香港提供收購或繼續租賃該等工廠的優先權。
金斯康香港亦將透過其直接全資附屬公司江蘇金斯瑞生物科技將以固定資產及現金出資的形式投資總計1.8億元人民幣,用於建設工廠、辦公大樓及其他倉儲設施,以擴大分子生物產能、細胞治療載體質粒技術的研究實驗室,及多(月太)GMP業務。相關公司之註冊資本將增加1,000萬美元。其建設預計將於2020年上半年至2021年九月進行。
另外金斯康香港將獲鎮江委員會提供若干扶持政策,包括為工程及技術人員提供免租公寓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.